Pulse Polio 2020: Tamil Nadu,Karantaka and Kerala are organizing the pulse polio immunisation camps tomorrow. Here's all you need to know

The Indian Pharmaceutical Alliance in its statement released on 15 January said: There was no discussion at all on the alleged bribes being given by pharma companies to doctors as being reported in the media

Wockhardt latest medicines: Wockhardt announces two new drugs for skin infections, its shares rise by 14 per cent intraday. Here's what this means

Wockhardt said the two approved new antibiotics, Emrok(IV) & Emrok O are used for acute bacterial skin and skin structure infections including diabetic foot infections and concurrent bacteraemia.

Share Market Update: During Thursday's trade, Sensex climbed to a fresh all-time high of 42,059 and Nifty too has hit a new lifetime high of 12,389 from 12,374.25 earlier.

Most in the Indian pharma industry are hopeful that the new National List of Essential Medicines (NLEM) expected in 2020 will not be too disruptive

TSSIA is meeting tomorrow to decide the future course of action, which includes a meeting of all Gramapanchayath heads and other authorities and the possibility of legal remedies: Ninad Jaywant

Wockhardt share price fell up to 6.42% intra day to Rs 281.5 compared to the previous close of Rs 300.80 on BSE

Morepen is trying to recover around Rs 1.55 crore, along with interest, from Wockhardt on account of the bills it raised between July 2018 and May 2019 for the medicines it supplied to the company.

Pharmaceutical firm Wockhardt on Wednesday reported narrowing of its consolidated net loss to Rs 44.98 crore for the quarter ended June 30, 2019.

Experts said markets overcame global jitters due to US-China trade war and turned their focus on the Lok Sabha election 2019.

Some of the generic companies, it points out, made unsolicited bids to customers of bigger players in cases where drug prices were high as a way to compete with a bigger generic player to grab a bigger share in the market. Interestingly, this exercise seems to have elements of attempts at trying to drive down prices to gain customers.

In separate clarifications to stock exchanges, the companies denied the accusations and stated they would defend themselves in the matter

Severe penalties could be levied on the Indian pharma companies varying from $13 million to $873 million; Glenmark could face the highest penalty, while Aurobindo the least.

The ongoing trade war between the US and China had triggered the recent correction in the market